"Le Centre Hospitalier Universitaire de Toulouse, constitué de plusieurs établissements répartis au nord et au sud de la ville, est un lieu d’accueil, d’hébergement et de soins au service de tous ceux qui, à un certain moment de leur vie, sont confrontés à la maladie et à la souffrance."

During the past decade, CHU de Toulouse - Hopital Rangueil conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 18 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 11 clinical trials were completed. i.e. 78.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU de Toulouse - Hopital Rangueil" #1 sponsor was "Celgene" with 7 trials, followed by "Centre Hospitalier Universitaire de Nīmes" with 7 trials sponsored, "Amgen" with 5 trials sponsored, "Pfizer" with 5 trials sponsored and "Hoffmann-La Roche" with 5 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU de Toulouse - Hopital Rangueil" #1 collaborator was "Gilead Sciences" with 2 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Cardialysis BV" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Otsuka Pharmaceutical Co., Ltd." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "CHU de Toulouse - Hopital Rangueil" are "Crohn's Disease" (7 trials), "Crohn Disease" (5 trials), "Ulcerative Colitis" (5 trials), "Coronary Artery Disease" (2 trials) and "Fibromyalgia" (2 trials). Many other conditions were trialed in "CHU de Toulouse - Hopital Rangueil" in a lesser frequency.

Most popular intervention types in "CHU de Toulouse - Hopital Rangueil" are "Drug" (45 trials), "Other" (15 trials), "Device" (3 trials), "Procedure" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "GED-0301" (3 trials), "Ozanimod" (3 trials), "Atezolizumab" (2 trials) and "Capecitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "CHU de Toulouse - Hopital Rangueil" are 54 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are 22 active trials in "CHU de Toulouse - Hopital Rangueil". 1 are not yet recruiting, 14 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 23 completed trials in CHU de Toulouse - Hopital Rangueil, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in CHU de Toulouse - Hopital Rangueil, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 5 trials that are defined as “Not Applicable".